Quarterly report pursuant to Section 13 or 15(d)

Goodwill and Other Intangible Assets (Tables)

v3.20.4
Goodwill and Other Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets from all acquisitions as of March 31, 2020 and December 31, 2019 are as follows:

 

          As Restated     As Restated  
          As of March 31, 2020     As of December 31, 2019  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
                   
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       6,719       6,719  
BioPharma acquisition:                        
Trademarks     10       1,600       1,600  
Customer relationships     8       5,700       5,700  
                         
CLIA Lab     2.3     $ 609     $ 609  
                         
Total           $ 39,288     $ 39,288  
                         
Accumulated Amortization           $ (24,554 )   $ (23,439 )
                         
Net Carrying Value           $ 14,734     $ 15,849  

Schedule of Goodwill Carrying Value

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2019 to March 31, 2020:

 

    Carrying  
    Amount  
Balance as of December 31, 2019   $ 8,433  
Adjustments     -  
Balance as of March 31, 2020   $ 8,433  
Schedule of Future Estimated Amortization Expense

Amortization expense was approximately $1.1 million and $0.9 million for the three-month periods ended March 31, 2020 and 2019, respectively. Estimated amortization expense for the next five years is as follows:

 

As Restated  
2020     2021     2022     2023     2024  
                                     
$ 4,871     $ 4,078     $ 2,156     $ 1,745     $ 873